Michael R Morin

US Patent:

20210347895, Nov 11, 2021

Filed:

Oct 17, 2019

Appl. No.:

17/283614

Inventors:

- Exton PA, US
Michael John MORIN - Salisbury MA, US

International Classification:

C07K 16/28

Abstract:

The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 (“PD-L1”) as a second exosome-associated protein. These bispecific antibodies can disrupt the suppression of anti-tumor activity by immune cells by targeting tumor-cell derived exosomes that inhibit T cell activation. Therefore, bispecific antibodies of the invention can be used in methods for treating cancers.

US Patent:

20210221914, Jul 22, 2021

Filed:

May 17, 2019

Appl. No.:

17/055646

Inventors:

- Exton PA, US
Michael John MORIN - Salisbury MA, US

Assignee:

IMMUNOME, INC. - Exton PA

International Classification:

C07K 16/42

Abstract:

This invention relates to the incorporation of one, or more, heterologous antibody epitopes into the AB, EF, or CD structural loops of the constant heavy domain 3 (“CH3 domain”) of an engineered antibody or Fc-linked therapeutic agent. The heterologous epitopes serve as “epitope tags” that are specifically detectable by epitope tag-specific detector antibodies, irrespective of the tagged agent's target specificity. Therefore, the epitope tags are useful for the rapid detection of any tagged antibody or Fc-linked agent in biological samples, including samples, which also contain endogenous antibodies.